Cml

[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Etiology ,[object Object],[object Object]

Epidemiology ,[object Object],[object Object]

Pathogenesis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Pathogenesis ,[object Object],[object Object],[object Object],[object Object]

Translocation t(9;22)(q34;q11)

Philadelphia Chromosome ,[object Object],[object Object]

The bcr/abl fusion protein ,[object Object],[object Object],[object Object],[object Object]

Clinical features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Laboratory features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Laboratory features (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Diagnosis ,[object Object],[object Object]

Accelerated phase of CML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Blast phase (blast crisis) of CML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Differential diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Prognostic factors ,[object Object],[object Object],[object Object],[object Object]

Treatment ,[object Object],[object Object],[object Object],[object Object]

Treatment Algorithm for treating CML DIAGNOSIS Imatinib for all Response to imatinib ‘ Failed” response to imatinib Continue Consider for other TKI or SCT

Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Tr ea tment Imatinib mesylate (Gleevec) ,[object Object],[object Object],[object Object],[object Object]

Response evaluation No response loss Anytime ‡ MMolR 18 Months CCgR 12 Months ‡ PCgR 6 Months CHR 3 Months Optimal response: Time:

Criteria of cytogenetic response >95 lack of response 36-95 minor 1-35 maior 0 complete % of Ph in bone marrow Cytogenetic response

Criteria of molecular response Maior molecular response: ≥ 3-log reduction of BCR/ABL transcript in RQ-PCR Complete molecular response: BCR/ABL transcript undetectable in PCR

Aditional T reatment ,[object Object],[object Object],[object Object],[object Object]

Treatment of patients with blast crisis ( AML phenotype ) ,[object Object],[object Object],[object Object]

Treatment of patients with blast crisis ( ALL phenotype ) ,[object Object],[object Object],[object Object],[object Object]

Cml

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (20)

Similar to Cml

Similar to Cml (20)

More from Jasmine John

More from Jasmine John (20)

Recently uploaded

Recently uploaded (20)

Cml